ipilimumab   Click here for help

GtoPdb Ligand ID: 6888

Synonyms: MDX-010 | MDX-101 | MDX-CTLA-4 | Yervoy®
Approved drug Immunopharmacology Ligand
ipilimumab is an approved drug (FDA and EMA (2011))
Compound class: Antibody
Comment: Ipilimumab is an anti-CTLA-4 monoclonal antibody. It is likely the subject of patent WO2001014424 [4], as antibody 10D1 which was investigated further, claimed in patent EP1503794 [1]. Ipilimumab is an immune checkpoint inhibitor.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Davis T, Keler T, Graziano R, Korman AJ. (2012)
Methods of treatement using ctla-4 antibodies.
Patent number: EP1503794. Assignee: Medarex, Inc.. Priority date: 12/04/2002. Publication date: 19/09/2012.
2. FDA. 
FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma.
Accessed on 18/04/2018. Modified on 18/04/2018. www.fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm?utm_campaign=Oncology%204%2F16%2F2018&utm_medium=email&utm_source=Eloqua&elqTrackId=461a88586a9a4db284ceb54da34a6a23&elq=8b10e118e0b249beb2807c129fc264e8&elqaid=3169&elqat=1&elqCampaignId=2374
3. FDA. 
Nivolumab in combination with ipilimumab.
Accessed on 17/06/2016. Modified on 17/06/2016. US Food and Drug Administration, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm
4. Halk EL, Korman AJ, Lonberg N. (2001)
Human ctla-4 antibodies and their uses.
Patent number: WO2001014424. Assignee: Medarex Inc. Priority date: 24/08/1999. Publication date: 01/03/2001.
5. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med, 373 (1): 23-34. [PMID:26027431]
6. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med, 378 (14): 1277-1290. [PMID:29562145]
7. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med, 372 (21): 2006-17. [PMID:25891304]